What Doreta Treats: Main Uses and Benefits

The combination analgesic is commonly used to help with symptoms related to physical discomfort and moderate to severe pain. It is considered relevant in situations where symptoms require additional support for management. The medicine is specifically indicated for the symptomatic treatment of such pain in patients whose condition requires this combination.

This supportive therapy is applied in clinical settings that involve acute or unstable symptom patterns, such as post-surgical recovery and following traumatic events. It is also relevant for easing symptoms that become disruptive during flares associated with conditions like severe osteoarthritis or certain forms of chronic lower back pain. The medication helps improve day-to-day comfort during periods of heightened symptoms, supporting the management of symptom clusters that may appear suddenly.

“This approach supports the patient during difficult episodes by easing distress.”

Quick Fact: Relief for Moderate to Severe Pain

The medication is commonly used across conditions presenting with acute episodes where the symptom intensity is high, and symptoms related to heightened physiological activity.

Regulatory References

1. Summary of Product Characteristics

Who Can and Cannot Use Doreta? (Official Regulatory Information)

Official labeling defines strict population eligibility rules for the use of the Tramadol/Paracetamol combination (Doreta), primarily based on age, organ function, and concurrent medical status. This medication is generally allowed for adults and adolescents aged 12 years and older who require symptomatic treatment for moderate to severe pain.

Contraindicated Populations (Must Not Use)

Use is contraindicated and explicitly prohibited in several population groups, including:

• Children younger than 12 years of age.
• Patients with severe hepatic impairment (severe liver failure).
• Individuals with significant respiratory depression or acute, severe bronchial asthma.
• Those in a state of acute intoxication with substances like alcohol or other opioids.
• Patients currently taking or having taken Monoamine Oxidase Inhibitors (MAOIs) within the last 14 days.

Conditional Use and Restrictions

Use is restricted or requires special consideration in other populations:

• Pregnancy and Breastfeeding: Use is generally not recommended during pregnancy due to the risk of neonatal opioid withdrawal syndrome, and should not be ingested while breastfeeding.
• Renal Impairment: Patients with severe renal impairment (Creatinine Clearance <10 mL/min) are generally not recommended to use the drug. For moderate impairment, the dosage interval must be extended.
• Older Adults (Over 75): Dosage intervals should be extended due to prolonged elimination.

Interactions with other medicines and products

Official regulatory documents define a structure of interactions based on the active ingredients, Tramadol and Paracetamol (Acetaminophen). This profile identifies substances that alter drug exposure or potentiate effects.

Contraindicated Combinations

Co-administration with Monoamine Oxidase Inhibitors (MAOIs) is formally contraindicated due to the risk of serotonergic syndrome. A mandatory separation of two weeks is required after stopping MAOIs before starting treatment. The product is also contraindicated with other products containing Paracetamol to avoid exceeding safe dose limits and risking hepatotoxicity.

Documented Pharmacokinetic and Pharmacodynamic Interactions

Population-Specific Interaction Notes

Severe hepatic impairment is an official contraindication due to heightened toxicity risk related to the Paracetamol component. For patients with renal impairment, the elimination of Tramadol is delayed, requiring careful consideration of prolonged dosing intervals.

The mechanism of Doreta modulates nociceptive signaling within the central nervous system (CNS) through two distinct, complementary mechanisms. The Tramadol component acts through a multimodal approach. Its active metabolite, O-desmethyltramadol (M1), functions as a weak agonist at the mu-Opioid Receptor (MOR), leading to inhibition of ascending nociceptive signal transmission. Concurrently, the parent drug weakly inhibits the reuptake of serotonin (SERT) and norepinephrine (NET), thereby enhancing descending pain-inhibitory signaling through involved neural pathways. The Paracetamol component modulates sensitivity by inhibiting Cyclooxygenase (COX) enzyme activity specifically within the CNS. This action reduces prostaglandin synthesis, altering the sensitivity of nociceptive pathways to afferent stimuli, and contributes to raising the central threshold for nociceptive signal activation. A key mechanistic constraint is the dependence of Tramadol's bioactivation on the polymorphic liver enzyme CYP2D6 for M1 production.

The administration of Doreta, a fixed-dose combination of Tramadol and Paracetamol, is governed by specific instructions. The medication is delivered via the oral route as a film-coated tablet and is designated exclusively for short-term use in managing acute pain.

Standardized Dosing and Frequency

The standardized regimen for adults and adolescents 12 years and older typically begins with an initial dose of two tablets (75 mg Tramadol / 650 mg Paracetamol).

The core of the usage pattern is the strict control over timing and quantity. Doses can be taken every four to six hours as needed, but the minimum interval between any two doses must be not less than six hours. Furthermore, the official instructions establish a maximum permitted intake of eight tablets (300 mg Tramadol / 2600 mg Paracetamol) within a 24-hour period. Tablets must be swallowed whole with liquid and may be administered with or without food. Concurrent use of any other product containing either Tramadol or Paracetamol is strictly prohibited.

Population-Specific Adjustments

Dosing requires adjustment for specific populations. For patients over 75 years of age, the interval between doses may be extended. For those with severe renal impairment (Creatinine Clearance <30 mL/min), the maximum allowable dose is typically reduced to two tablets every 12 hours. The medicine is not recommended for children under 12 years of age. If the medication has been used for a prolonged period, discontinuation should be managed by gradually reducing the dose.

Recent Clinical Evidence

The fixed-dose combination of tramadol and paracetamol (Doreta) has been evaluated in various clinical settings for the management of moderate to severe pain. The combination utilizes the distinct mechanisms of action of its two components to potentially offer a multimodal approach to pain relief.

Clinical Trial Findings

Acute and Post-Operative Pain

Multiple randomized controlled trials (RCTs) have focused on the combination's use in acute post-operative pain, including following major surgery. Studies have explored whether the combination was associated with greater pain reduction compared to placebo or monotherapy with either component.

Research suggests that the combination may achieve supra-additive analgesic effects, meaning the combined response was greater than the sum of the individual components' effects when administered alone. This was observed across different assessments of pain intensity.

Chronic Pain and Osteoarthritis

The tramadol/paracetamol fixed-dose combination has also been evaluated in patients with chronic pain conditions, such as osteoarthritis (OA) and chronic lower back pain.

• Systematic Reviews: Analyses of trials involving patients with OA have explored the combination's influence on pain and physical function scores, often measured using tools like the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC). While some studies noted a benefit on pain relief and function compared to placebo, the overall observed change in mean pain and function was generally reported as small.
• Adverse Events: Across clinical evaluations, the incidence and severity of reported adverse events were generally found to be consistent with the known profiles of the individual components, tramadol and paracetamol. Nausea, dizziness, and somnolence were frequently reported during research follow-up periods.

How to Store and Dispose of Doreta (Tramadol Hydrochloride and Paracetamol)

The storage and disposal instructions for Doreta are governed by regulatory requirements to ensure product stability and prevent accidental access to the opioid component, Tramadol.

Storage Conditions

Official Disposal Rules

Unused or expired Doreta must be disposed of in accordance with local regulations for pharmaceutical waste. Do not throw the medicine away via household trash or wastewater. The U.S. FDA recommends using a drug take-back program or a mail-back envelope as the safest method. If those options are not available, the FDA has authorized flushing Tramadol-containing products down the toilet to immediately remove the drug from the home and prevent accidental poisoning.